Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

Logo
IQV US​

Iqvia Holdings Inc.(IQV US)

$279.36+1.040.37%Ext:$281.67+2.310.83%(Market Closed · 23:56:11 UTC)

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Iqvia Holdings Inc. — Company Profile

IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.

Sector
Industrials
Industry
Professional Services
Exchange
UN
CEO
Ari Bousbib
Headquarters
Durham, NC, US
IPO Date
May 9, 2013
Employees
94,000
Website
www.iqvia.com

Key Metrics

Price
$258.21
Market Cap
$42.50B
Revenue (TTM)
$4.15B
Net Income (TTM)
$274.00M
EPS (TTM)
1.63
P/E (TTM)
30.69
P/B (TTM)
6.83
Dividend Yield
0.00%
ROE (TTM)
4.40%
ROA (TTM)
0.92%
Operating Margin
12.38%
Beta
0.76

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.

Website
www.iqvia.com
Location
Durham, NC, US
Phone919 998 2000
Employees94,000
CEOAri Bousbib
Sector
Industrials
Industry
Professional Services
IPO DateMay 9, 2013

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.

Latest Documents

SEC Filings(1.1K)

Expand
  • 8-KEntry into a Material Definitive Agreement23 Sep
  • 8-KIQVIA Announces Offering of Senior Notes9 Sep
  • 4Statement of changes in beneficial ownership4 Sep
  • 144Berkshire James G.2 Sep
  • 4Statement of changes in beneficial ownership4 Aug
  • 4Statement of changes in beneficial ownership4 Aug
  • 144STAUB W RICHARD3 Aug
  • 4Statement of changes in beneficial ownership31 Jul
  • 4Statement of changes in beneficial ownership31 Jul
  • 4Statement of changes in beneficial ownership31 Jul
  • 144Patel Bhavik31 Jul
  • 144Cherofsky Keriann29 Jul
  • 144Sherbet Eric29 Jul
  • 144BOUSBIB ARI29 Jul
  • 10-QQ2ended 30 Jun 202628 Jul
  • 8-KResults of Operations and Financial Condition28 Jul
  • 4Statement of changes in beneficial ownership16 Jul
  • 4Statement of changes in beneficial ownership16 Jul
  • 4Statement of changes in beneficial ownership16 Jul
  • 4Statement of changes in beneficial ownership16 Jul

News

  • IQVIA Gears Up to Post Q3 Earnings: Here's What Investors Should Know22 Oct
  • IQVIA: R&D Bookings Are Reaccelerating, But The Valuation Now Requires Execution20 Oct
  • IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy?20 Oct
  • IQVIA Holdings Inc. $IQV Stock: Maia Wealth LLC Reduces Stake20 Oct
  • First Citizens Bank & Trust Co. Makes New $1.39 Million Investment in IQVIA Holdings Inc. $IQV16 Oct
  • IQVIA Selects Veeva Clinical Operations Applications13 Oct
  • IQVIA Selects Veeva Clinical Operations Applications13 Oct
  • Here's Why IQVIA Holdings (IQV) is a Strong Momentum Stock8 Oct
  • IQVIA Launches IQVIA Life Science Models to Help Life Sciences Companies Predict Clinical Trial Outcomes7 Oct
  • IQVIA Launches IQVIA Explorer to Help Life Sciences Companies Make Better Commercial Decisions7 Oct
  • Extensive Database & Solid Bookings Benefit IQVIA Amid Low Liquidity2 Oct
  • Rep. Kevin Hern Unloads Shares of Honeywell International Inc. (NASDAQ:HON)29 Sep
  • Crane (NYSE:CR) Stock Sold Off by Rep. Kevin Hern29 Sep
  • Colgate-Palmolive (NYSE:CL) Stock Sale Revealed by Rep. Kevin Hern29 Sep
  • Walmart (NASDAQ:WMT) Shares Unloaded by Rep. Kevin Hern29 Sep
  • Novo Nordisk A/S (NYSE:NVO) Stock Sold Off by Rep. Kevin Hern29 Sep
  • Rep. Kevin Hern Sells Shares of Devon Energy Corporation (NYSE:DVN)29 Sep
  • Danaher (NYSE:DHR) Stock Unloaded by Rep. Kevin Hern29 Sep
  • Rep. Kevin Hern Sells Shares of ONEOK, Inc. (NYSE:OKE)29 Sep
  • Pembina Pipeline (NYSE:PBA) Stock Sold by Rep. Kevin Hern29 Sep

Mentions in Filings

  • … are trademarks registered in the name of Dr. Reddy’s Laboratories Limited or are pending before the respective trademark registries, unless otherwise specified. Market share data is based on information provided by <strong>IQVIA Holdings Inc.</strong> (formerly Quintiles IMS Holdings Inc.) (“IQVIA”), a provider of market research to the pharmaceutical industry, unless otherwise stated. References to “HUF” are to a Hindu Undivided Family, a form of entity found in …
    DR REDDYS LABORATORIES LTDIqvia Holdings Inc.·6-K - Current report (foreign private issuer)·Q3 27·23 Oct
  • … ions from providers that make applications geared toward the life sciences industry. Our CRM solutions primarily compete with Salesforce, Inc., which has developed a life sciences industry-specific CRM application. <strong>IQVIA Holdings Inc.</strong>, which historically offered a competitive CRM solution, has licensed its CRM software to Salesforce. Our Veeva Data Cloud products as well as Veeva Crossix, compete with IQVIA, Ipsos Group S.A., Definitive Health Co …
    VEEVA SYSTEMS INCIqvia Holdings Inc.·10-Q - Quarterly report Q2·Q2 27·27 Aug
  • #\*Iovance Biotherapeutics, Inc. 49,131 125,284 \*IQVIA Holdings, Inc. 48,721 11,213,138 iRadimed Corp. 1,493 146,135 \*Ironwood Pharmaceuticals, Inc., Class A 626 3,061 \*Jazz Pharmaceuticals PLC 15,743 2,589,566 Johnson & Johnson 690,976 157,024,296 \* Keros Therapeutics, Inc. 1,693 30,322 \*Kewaunee Scientific Corp. 684 27,045 \* Kiniksa Pharmaceuticals International PLC, Class A 10,659 468,143 …
    Dimensional ETF TrustIqvia Holdings Inc.·NPORT-EX - NT NPORT-P - Notification of late filing (portfolio holdings)·Q1 26·13 Aug
  • … oduced differently” than display ads. Id. at 126-32. 106.Social media ads and display ads likewise serve different purposes and are therefore not substitutes, as a Court in this District recently found. See FTC v. <strong>IQVIA Holdings Inc.</strong>, 710 F. Supp. 3d 329, 367-68 (S.D.N.Y. 2024). Social media ads appear in a user’s social media feed and are targeted to users based on the social media content they read or watch. Display ads, by contrast, are often …
    Teads Holding Co.Iqvia Holdings Inc.·EX-99.2 - 8-K - Regulation FD Disclosure·Q3 26·3 Aug
  • … in characterizing the potential patient value for Oxnimbi. Each year, approximately three million people are newly diagnosed according to Komodo Health, Inc.’s (Komodo) medical claims database. Our analysis of U.S. <strong>IQVIA Holdings Inc.</strong> (NYSE: IQV) (IQVIA) claims data indicates that over a five-year period from 2019 to 2024, approximately 23 million unique patients with a diagnosis of OSA were active within the healthcare system. Research from the …
    Apnimed, Inc.Iqvia Holdings Inc.·424B4 - Prospectus filing (Rule 424(b)(4))·Q3 26·31 Jul
  • … 11 | Elevance Health, Inc. | 428.090 | 4,708.99 | | | 20 | Globus Medical, Inc. - CL A | 76.310 | 1,526.20 | | | 40 | Harmony Biosciences Holdings, Inc. | 37.510 | 1,500.40 | | | 10 | HCA Healthcare, Inc. | 470.440 | 4,704.40 | | | 17 | <strong>IQVIA Holdings</strong>, Inc. | 262.010 | 4,454.17 | | | 6 | Tenet Healthcare Corporation | 271.600 | 1,629.60 | | | 15 | Veeva Systems, Inc. - CL A | 297.350 | 4,460.25 | | | 254 | Viatris, Inc. | 17.440 | 4,429.76 | 10
    Invesco Unit Trusts Series 2502Iqvia Holdings Inc.·487 - VKUT 2502·Q4 26·15 Oct

Key Stats

Trading

Px/Chg 1D$258.21 / -0.96%
Avg Volume1.80M
Beta0.76
Mkt Cap42.50B
FD Mkt Cap42.42B

Float

Shrs Out/Float164.60M / 156.25M
Short Float0.03%
Days to Cover2.74
Stock Repurchased$552.00M

Current Valuation

EV56.75B
EV/EBITDA16.13
EV/Sales3.41
P/B6.83
P/S2.56
FCF Yield1.16%
ROE4.40%
ROA0.92%
Current Ratio0.75

Estimates

P/E30.69
Est P/EN/A
Est EPSN/A
Est PEGN/A

Valuation

Metric5Yr AvgApr '23May '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings58.3131.5831.5320.1153.23155.11
Price / Sales4.712.392.861.796.2710.24
Price / Book Value5.715.987.004.554.216.83
Price / Free Cash Flow39.7321.7228.5413.0648.7786.56
ENTERPRISE VALUE METRICS
Enterprise Value48,015.646,249.655,334.440,066.041,680.856,747.4
Enterprise Value / Sales6.553.213.692.609.5513.67
Enterprise Value / EBITDA30.9115.9016.9911.6039.8170.23
Enterprise Value / EBIT47.0626.0025.9717.1357.10109.13

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue4.1%13,874.014,410.014,984.015,405.016,310.0
Gross Income-2%4,641.05,028.05,239.05,375.04,286.0
EBITDA5.8%2,767.02,909.03,256.03,453.03,464.0
EBIT11.5%1,503.01,779.02,131.02,339.02,320.0
Net Income8.9%966.01,091.01,358.01,373.01,360.0
EPS (Diluted)12.2%4.955.727.297.497.84
BALANCE SHEET
Cash & ST Inv9.7%1,477.01,309.01,496.01,843.02,141.0
Total Assets4.9%24,689.025,337.026,681.026,899.029,944.0
Total Liabilities5.7%18,647.019,572.020,569.020,832.023,314.0
Total Shareholder Equity1.9%6,042.05,765.06,112.06,067.06,503.0
CASH FLOW
Net Operating Cash Flow-2.5%2,942.02,260.02,149.02,716.02,654.0
Cap Ex-1.5%-640.0-674.0-649.0-602.0-603.0
Free Cash Flow-2.8%2,302.01,586.01,500.02,114.02,051.0

Enterprise Value Bridge

Millions USD23 Oct '26
Price (As of 23 Oct '26)277.99
Basic Shares164.60
Market Cap45,757.2
Diluted Shares169.80
Fully Diluted Shares Outstanding169.80
Fully Diluted Market Cap47,202.7
+Consolidated Debt16,065.0
−In-the-Money Convertible Debt—
+Capital Leases232.0
+Operating Leases—
−Cash & Equivalents-1,947.0
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest128.0
+Pension Liabilities—
Enterprise Value60,003.2

Segment data

Revenue

by Products and services

  • Research And Development Solutions55%
  • Technology And Analytics Solutions41%
  • Contract Sales And Medical Solutions5%

Revenue

by Geography

  • Americas47%
  • Emea32%
  • Asia Pacific21%

Related companies

Wanhua Chemical Group Co., Ltd.

600309 CG

Novozymes As/fi

NVZMY US

DSM-Firmenich AG/ADR

DSFIR NA

L Air Liquide Sa /FI

AIQUY US

EMS-Chemie Holding AG/ADR

EMSHF US

Incyte Corp

INCY US

Grace Fabric Technology Co.,Ltd.

603256 CG

Medpace Holdings, Inc.

MEDP US

Nippon Paint Holdings Co., Ltd.

NPCPF US

Covestro AG/ADR

COVTY US

Symrise AG

SYIEY US

Charles River Laboratories International, Inc.

CRL US